Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 75/100

Insmed To Present at the SVB Securities Global Biopharma Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Key Takeaway: Insmed Incorporated, a biopharmaceutical company focused on serious and rare diseases, announced its participation in the SVB Securities Global Biopharma Conference on February 14, 2023. The management will engage in a fireside chat that will be accessible via webcast. Insmed is recognized for its first-in-disease therapy approved in the US, Europe, and Japan, and is advancing a pipeline aimed at addressing unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is actively engaged in presenting its innovations at key industry conferences.
  • The company has a robust pipeline targeting serious unmet medical needs.
  • Insmed's first commercial product has received approval in major markets.

Full Press Release Details

BRIDGEWATER, N.J. , Feb. 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 12:00 p.m. ET .
The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . The webcast will be archived for a period of 30 days following the conclusion of the live event.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a footprint across Europe and in Japan. For more information, visit www.insmed.com .
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

When will Insmed present at the Global Biopharma Conference?

Insmed will present on February 14, 2023, at 12:00 p.m. ET.

How can I access the Insmed fireside chat?

The chat will be available via the investor relations section on Insmed's website.

What is Insmed's primary focus?

Insmed aims to transform the lives of patients with serious and rare diseases.

Where is Insmed headquartered?

Insmed is headquartered in Bridgewater, New Jersey.

What type of therapies is Insmed developing?

Insmed is developing therapies for neutrophil-mediated inflammatory diseases and rare disorders.

Last updated: Feb 7, 2023